tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EXEL Stock Latest News

Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
Company AnnouncementsExelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
2d ago
EXEL
Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
PremiumCompany Announcements
Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
2d ago
EXEL
Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating
PremiumRatings
Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating
4d ago
EXEL
Exelixis Announces New Executive VP for R&D
PremiumCompany Announcements
Exelixis Announces New Executive VP for R&D
11d ago
8K
EXEL
Exelixis’s Promising Study on XB371: A New Hope for Solid Tumors
PremiumCompany Announcements
Exelixis’s Promising Study on XB371: A New Hope for Solid Tumors
12d ago
EXEL
Exelixis and Novartis: Key Updates from the Pan Tumor Rollover Study
PremiumCompany AnnouncementsExelixis and Novartis: Key Updates from the Pan Tumor Rollover Study
13d ago
EXEL
Exelixis’s Promising Study on Renal Cell Carcinoma: A Potential Game Changer?
Premium
Company Announcements
Exelixis’s Promising Study on Renal Cell Carcinoma: A Potential Game Changer?
16d ago
EXEL
Exelixis’s Innovative RCC Study: A Potential Game-Changer?
Premium
Company Announcements
Exelixis’s Innovative RCC Study: A Potential Game-Changer?
20d ago
EXEL
Exelixis’s Promising Study on Renal Cell Carcinoma: Key Updates for Investors
PremiumCompany Announcements
Exelixis’s Promising Study on Renal Cell Carcinoma: Key Updates for Investors
21d ago
EXEL
Pan-Tumor Rollover Study: A New Horizon in Long-term Cancer Treatment
PremiumCompany Announcements
Pan-Tumor Rollover Study: A New Horizon in Long-term Cancer Treatment
25d ago
BMY
NVS
Exelixis price target lowered to $46 from $53 at H.C. Wainwright
PremiumThe Fly
Exelixis price target lowered to $46 from $53 at H.C. Wainwright
28d ago
EXEL
Exelixis and Merck’s Promising Study on Renal Cell Carcinoma Treatment
PremiumCompany Announcements
Exelixis and Merck’s Promising Study on Renal Cell Carcinoma Treatment
1M ago
EXEL
Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
PremiumCompany AnnouncementsPan-Tumor Rollover Study: A New Horizon in Cancer Treatment
1M ago
BMY
NVS
Exelixis price target lowered to $38 from $43 at UBS
Premium
The Fly
Exelixis price target lowered to $38 from $43 at UBS
1M ago
EXEL
Exelixis Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Exelixis Earnings Call: Growth Amid Challenges
1M ago
EXEL
Exelixis falls -16.7%
PremiumThe Fly
Exelixis falls -16.7%
1M ago
EXEL
Exelixis falls -15.7%
PremiumThe Fly
Exelixis falls -15.7%
1M ago
EXEL
Exelixis price target lowered to $46 from $48 at Morgan Stanley
PremiumThe Fly
Exelixis price target lowered to $46 from $48 at Morgan Stanley
1M ago
EXEL
Exelixis price target lowered to $49 from $56 at Truist
PremiumThe Fly
Exelixis price target lowered to $49 from $56 at Truist
1M ago
EXEL
Exelixis price target lowered to $45 from $50 at RBC Capital
PremiumThe FlyExelixis price target lowered to $45 from $50 at RBC Capital
1M ago
EXEL
Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
Premium
Ratings
Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
1M ago
EXEL
Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns
Premium
Ratings
Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns
1M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >